Mechanisms of action of tumor necrosis factor antagonists and granulomatous infections

Journal of Rheumatology

Volumn 31, Issue 10, 2004, Pages 1888-1892

  Beenhouwer, David ^a   Wallis, Robert ^b   Broder, Michael ^c   Furst, Daniel E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^c Zynx Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; CYTOKINE; ETANERCEPT; INFLIXIMAB; MONOCLONAL ANTIBODY; RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

APOPTOSIS; ASPERGILLUS; CLINICAL TRIAL; CRYPTOCOCCUS NEOFORMANS; CYTOKINE RELEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EDITORIAL; GRANULOMA; GRANULOMATOSIS; HEMATOLOGIC DISEASE; HISTOPLASMA CAPSULATUM; HISTOPLASMOSIS; HUMAN; IMMUNITY; INFECTION; INFLAMMATION; LISTERIA MONOCYTOGENES; MONOCYTOPENIA; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; TUBERCULOSIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; GRANULOMATOUS DISEASE, CHRONIC; HUMANS; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 5044237122     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (57)

1. Alarcon GS. Methotrexate use in rheumatoid arthritis. A clinician's perspective. Immunopharmacology 2000;47:259-71.
2. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
3. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602.
4. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-9.
5. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
6. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to rumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35.
7. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
8. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
9. Gluck T, Linde HJ, Scholmerich J, et al. Anti-tumor necrosis factor therapy and Listeria monocytogenes infection: report of two cases. Arthritis Rheum 2002;46:2255-7.
10. Kamath BM, Mamula P, Baldassano RN, Markowitz JE. Listeria meningitis after treatment with infliximab. J Pediatr Gastroenterol Nutr 2002;34:410-2.
11. Lee JH, Slifman NR, Gershon SK, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002;46:2565-70.
12. Nunez MO, Ripoll NC, Cameras Martin JA, Gonzalez Lara V, Gregorio Maranon HG. Reactivation tuberculosis in a patient with anti-TNF-alpha treatment [letter]. Am J Gastroenterol 2001;96:1665-6.
13. Nakelchik M, Mangino JE. Reactivation of histoplasmosis after treatment with infliximab. Am J Med 2002;112:78.
14. True DG, Penmetcha M, Peckham SJ. Disseminated cryptococcal infection in rheumatoid arthritis treated with methotrexate and infliximab. J Rheumatol 2002;29:1561-3.
15. Warris A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 2001;344:1099-100.
16. Liberopoulos EN, Drosos AA, Elisaf MS. Exacerbation of tuberculosis enteritis after treatment with infliximab [letter]. Am J Med 2002;113:615.
17. Wallis R, Broder M, Wong J, Hanson M, Beenhouwer D. Granulomatous infectious diseases associated with tumor necrosis factor (TNF) antagonists. Clin Infect Dis 2004;38:1261-5 [erratum in press].
18. Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997;385:729-33.
19. Roach DR, Bean AG, Demangel C, et al. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 2002;168:4620-7.
20. Robak T, Gladalska A, Stepien H. The tumour necrosis factor family of receptors/ligands in the serum of patients with rheumatoid arthritis. Eur Cytokine Netw 1998;9:145-54.
21. Murch SH, Lamkin VA, Savage MO, Walker-Smith JA, MacDonald TT. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 1991;32:913-7.
22. Nurnberger W, Platonov A, Stannigel H, et al. Definition of a new score for severity of generalized Neisseria meningitidis infection. Eur J Pediatr 1995;154:896-900.
23. Smith-Oliver T, Noel LS, Stimpson SS, Yarnall DP, Connolly KM. Elevated levels of TNF in the joints of adjuvant arthritic rats. Cytokine 1993;5:298-304.
24. Steiner G, Tohidast-Akrad M, Witzmann G, et al. Cytokine production by synovial T cells in rheumatoid arthritis. Rheumatology Oxford 1999;38:202-13.
25. Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992;339:89-91.
26. Schaible UE, Collins HL, Kaufmann SH. Confrontation between intracellular bacteria and the immune system. Adv Immunol 1999;71:267-377.
27. Zumla A, James D. Granulomatous infections: etiology and classification. Clin Infect Dis 1996;23:146-58.
28. Flynn JL, Goldstein MM, Chan J, et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995;2:561-72.
29. Bean AG, Roach DR, Briscoe H, et al. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J Immunol 1999;162:3504-11.
30. Flesch IE, Kaufmann SH. Mechanisms involved in mycobacterial growth inhibition by gamma interferon-activated bone marrow macrophages: role of reactive nitrogen intermediates. Infect Immun 1991;59:3213-8.
31. Turner J, Frank AA, Brooks JV, Marietta PM, Orme IM. Pentoxifylline treatment of mice with chronic pulmonary tuberculosis accelerates the development of destructive pathology. Immunology 2001;102:248-53.
32. Kindler V, Sappino AP, Grau GE, Piguet PF, Vassalli P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989;56:731-40.
33. Roach DR, Briscoe H, Saunders B, et al. Secreted lymphotoxin-alpha is essential for the control of an intracellular bacterial infection. J Exp Med 2001;193:239-46.
34. Larkin R, Benjamin CD, Hsu YM, et al. CD40 ligand (CD154) does not contribute to lymphocyte-mediated inhibition of virulent Mycobacterium tuberculosis within human monocytes. Infect Immun 2002;70:4716-20.
35. Stenger S, Hanson DA, Teitelbaum R, et al. An antimicrobial activity of cytolytic T cells mediated by granulysin. Science 1998;282:121-5.
36. Thoma-Uszynski S, Stenger S, Takeuchi O, et al. Induction of direct antimicrobial activity through mammalian toll-like receptors. Science 2001;291:1544-7.
37. Slifman NR, Gershon SK, Lee JH, Edwards ET, Braun MM. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum 2003;48:319-24.
38. Stephens MC, Shepanski MA, Mamula P, et al. Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center. Am J Gastroenterol 2003;98:104-11.
39. Abbott Laboratories. FDA Advisory Committee Meeting Briefing Document for Adalimumab; 3-4-2003. Abbott Laboratories.
40. Ruderman E, Markenson J. Granulomatous infections and tumor necrosis factor antagonist therapies [abstract]. European League Against Rheumatism Congress, 2003:209. Internet, [cited June 4, 2004] Available from http://www.eular.org/index.cfm
41. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD, BIOBADASERGroup. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003;48:2122-7.
42. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004;38:1261-5.
43. Wyeth Pharmaceuticals and Amgen. Etanercept (Enbrel®) Prescribing Information. Package Insert. 2002.
44. Centocor. Infliximab (Remicade®) Prescribing Information. Package Insert. 2003.
45. Abbott Laboratories. Humira (adalimumab) Prescribing Information. Package Insert. 2003.
46. Santora LC, Kaymakcalan Z, Sakorafas P, Krull IS, Grant K. Characterization of noncovalent complexes of recombinant human monoclonal antibody and antigen using cation exchange, size exclusion chromatography, and BIAcore. Anal Biochem 2001;299:119-29.
47. Scallon B, Cai A, Solowski N, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002;301:418-26.
48. Siegel SA, Shealy DJ, Nakada MT, et al. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. Cytokine 1995;7:15-25.
49. Davis T, Friend D, Smith C. Comparative TNF binding characteristics of etanercept (Enbrel) and infliximab (Remicade). Ann Rheum Dis 2002;61:184.
50. Committee for Proprietary Medicinal Products (CPMP). Scientific discussion - Remicade. European Agency for the Evaluation of Medicinal Products. 2002. CPMP/19011.99. Internet [cited July 19, 2004], Available from: http://www.emea.eu.int/humandocs/PDFS/EPAR/Remicade/190199en6.pdf
51. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995;7:251-9.
52. Lorenz HM, Antoni C, Valerius T, et al. In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis. Short term cellular and molecular effects. J Immunol 1996;156:1646-53.
53. Barone D, Krantz C, Lambert D, Maggiora K, Mohler K. Comparative analysis of the ability of etanercept and infliximab to lyse TNF-expressing cells in a complement dependent fashion [abstract]. Arthritis Rheum 1999;42 Suppl: S90.
54. Baert FJ, D'Haens GR, Peelers M, et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999;116:22-8.
55. ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002;50:206-11.
56. Van Den Brande JM, Braat H, Van Den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003;124:1774-85.
57. Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases. Ann Rheum Dis 2003;62:2-9.